Argos Therapeutics' (ARGS) CEO Jeff Abbey on Q2 2014 Results - Earnings Call Transcript

| About: Argos Therapeutics, (ARGS)

Argos Therapeutics, Inc. (NASDAQ:ARGS)

Q2 2014 Earnings Conference Call

August 13, 2014 4:30 PM ET


Lori Harrelson – VP, Finance

Jeff Abbey – President and CEO

Doug Plessinger – VP, Clinical and Medical Affairs

Charles Nicolette – Chief Scientific Officer and VP, Research and Development


Chad Messer – Needham & Company

Roy Buchanan – Piper Jaffray

Charles Duncan – Piper Jaffray

Tom Schrader – Stifel Nicolaus


Good afternoon, ladies and gentlemen, and welcome to the Argos Therapeutics Second Quarter 2014 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will be given at that time. (Operator Instructions) As a reminder, today’s conference is being recorded.

I would now like to turn the conference call over to your host, Lori Harrelson, Vice President of Finance. Ms. Harrelson, please go ahead.

Lori Harrelson

Good afternoon, and thank you for joining us today for our second quarter 2014 financial results conference call. Joining me on the call today are, Jeff Abbey, President and Chief Executive Officer; Dr. Charles Nicolette, Chief Scientific Officer and Vice President of Research and Development; and Doug Plessinger, Vice President of Clinical and Medical Affairs.

Before we get started, I would like to point out that an archived webcast of this conference call will be made available in the Investors section of our website following today’s call.

Today’s press release includes our recent highlights and 2014 anticipated milestones, and second quarter 2014 financial results. I would also like to point out that various remarks that we may make during this call about the company’s future expectations, plans and prospects, including statements about the company and other statements, containing the words, believes, anticipates, plans, expects, and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.

Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our Quarterly Report on Form 10-Q. In addition, any forward-looking statements presented on this call represent our views only as of today, and should be relied upon, as representing our views as of any subsequent date.

We anticipate that subsequent events and developments may cause our views to change. However while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to today.

I would now turn the call over to Jeff.

Jeff Abbey

Thank you, Lori. Good afternoon, everyone, and thank you for joining us on our call today. We are pleased with the progress Argos has made over the last few months. Most importantly, we are on track with our plans to complete tumor collection for all patients for the ADAPT phase 3 trial of AGS-003 in metastatic renal cell carcinoma or mRCC by the end of the year, and to complete enrollment and randomization in the first quarter of next year.

At the annual meeting of the American Society of Clinical Oncology or ASCO held earlier this year, we presented updated overall survival data from our completed phase 2 trial of AGS-003 in mRCC patients.

Median overall survival for all patients in the trial was 30.2 months, slightly more than double that for similar risk mRCC patients treated with Sutent in the international mRCC Consortium Database. Moreover, the median overall survival for intermediate risk mRCC patients in the trial was 57.1 months, which compares to 20.5 months for intermediate risk mRCC patients treated with Sutent alone, from data presented during the 2014 Genitourinary Cancers Symposium.

These results in poor and intermediate risk mRCC patients are highly encouraging, and we are hopeful that they will be confirmed in our ADAPT phase 3 trial. Doug will provide further details of our AGS-003 program in just a few moments.

Turning to AGS-004, we recently presented data from the completed phase 2 trial at the International AIDS Society Cure Symposium, which demonstrates that viral load control was associated with low viral sequence diversity, indicating that AGS-004 decreased viral replication. We are encouraged that AGS-004 is having a positive effect on the immune system of HIV patients, and we look forward to sharing key data from our phase 2b clinical trial of AGS-004 in chronically infected HIV patients in the coming weeks.

Later in the call, Charles will discuss the status of our AGS-004 program, as well as provide an update of our pre-clinical CD83 program, which we believe has significant potential to treat autoimmune and inflammatory disorders, as well as transplantation rejection.

But first, I will turn the call over to Doug who will review our AGS-003 program.

Doug Plessinger

Thanks Jeff. Our Arcelis immunotherapy platform is designed to overcome the disease-induced immunosuppression that exists in patients, and to stimulate the patient’s own immune system to activate a long lasting memory T cell response, specific to their disease with limited toxicity.

The Arcelis platform enables us to engineer fully personalized immunotherapy products, like AGS-003 and AGS-004 for a wide range of cancers and infectious diseases. As Jeff mentioned, at this past ASCO, we presented updated survival data from our phase 2 clinical trial of AGS-003 in combination with Sutent.

In addition to the data Jeff discussed earlier, we presented data showing that in 33% of patients survived for greater than 4.5 years, and 23% for more than five years, with two patients remaining in long-term remission for longer than five years.

We believe that these long-term survival data are unexpected for poor intermediate risk patients treated with Sutent for targeted therapy alone.

As Jeff said, we continue to be pleased with our enrollment for patients in the pivotal phase 3 ADAPT trial, which is evaluating AGS-003 in combination with targeted therapy versus targeted therapy alone in 450 newly diagnosed mRCC patients.

The single pivotal phase 3 trial is being conducted under a Special Protocol Assessment or SPA. This ADAPT trial is similar in design to our phase 2 combination trial, with a few modifications, which we believe make it an optimal trial to evaluate the efficacy of AGS-003.

In the ADAPT phase 3 trial, we are allowing dosing through early progression to ensure we deliver five or more AGS-003 doses, which were shown in our phase 2 trials to be associated with the memory T cell response that correlated a prolonged survival and progression free survival and improved tumor response.

Second, the trial offers real-world flexibility to our investigators, as we allow them to switch from Sutent to other approved addable targeted therapies, either due to early progression or to address the significant toxicity, commonly observed with Sutent.

Finally, we adjusted the eligibility criteria to eliminate the post-prognosis patients we included in past trials who have a limited chance to respond to targeted therapy in an expected survival of less than six months.

With this adjustment in eligibility, approximately 70% of enrolled patients to-date are intermediate risk patients. This is important because we expect the intermediate risk patients enrolled in the ADAPT trial to drive the median overall survival outcomes. And recall that as Jeff mentioned, in our phase 2 combination trial, the median survival for intermediate risk patient was nearly five years, despite the fact that we did not dose beyond early progression as we will do in these phase 3 ADAPT trial.

This is three times the survival we would expect in similar risk patients when treated with Sutent alone.

As of July 31, 2014, we had collected tumor from approximately 530 patients for screening, for eligibility to treatment phase of the ADAPT trial, and enrolled in randomized more than 190 patients. We expect to complete tumor collection for approximately 900 patients by the end of 2014, and to complete enrollment and randomization of 450 fully eligible patients in the first quarter of next year.

We expect the planned interim safety, utility and efficacy analysis to occur in 2015 and the primary trial analysis and un-blinding of results to occur in mid-2016. Later this year, we expect to initiate multiple phase 2 studies of AGS-003 in early state RCC, non-clear cell mRCC and other solid tumors.

We hope to have preliminary data from these trials, demonstrating the immunologic effects of AGS-003 on the induction of memory T cells sometime in 2015, within a year of initiating these studies.

Now, I would like to turn the call over to Charles, who will review our development of AGS-004, our Arcelis therapy for HIV, and provide an update of our development efforts of CD83, our pre-clinical program for autoimmune and inflammatory disorders and transplantation rejection.

Charles Nicolette

Thanks, Doug. As Jeff mentioned earlier, in coming weeks, we expect to release key data from our proof of concept double-blind placebo-controlled phase 2b HIV clinical trial of AGS-004. I want to point out that the analyses of the data being conducted are extraordinarily complex, and to ensure accuracy, are being conducted thoroughly, by multiple independent groups who are working as quickly as possible.

As a reminder, the phase 2b trial enrolled 53 chronically infected HIV patients. Patients with chronic HIV infection are those, who have initiated anti-retroviral drug therapy or ART at least six months after the initial infection.

The primary endpoint of this trial is a comparison between the mediate viral load levels of the AGS-004 treated cohort and the placebo treated cohort at the 12-week of ART interruption. In addition, we will also be presenting an analysis of immune responses induced, before and after ART treatment interruption, which we believe is critically important.

We are particularly interested to see where the memory T cell responses were induced in the AGS-004 treated cohort and/or in the placebo treated cohort, and if so, what the impact may have been on viral load and virus replication.

Observing memory T cell responses that result in lower viral loads in AGS-004 treated patients would indicate that the immune responses generated are able to reduce viral replication.

In addition, if the data shows that AGS-004 successfully induced memory T cell responses in chronically infected HIV patients, we believe this would further validate our Arcelis technology platform and its potential to generate efficacious products for the treatment of not just HIV but cancer as well.

We recently presented evidence of this from a follow-up sub-study of our previously completed phase 2 trial at the International AIDS Society HIV Cure Symposium in Melbourne, Australia in July. The data showed that prolonged control of viral load after AGS-004 administration was associated with decreased viral genetic diversity, which is consistent with immune-based suppression of viral replication.

As a reminder, the phase 2 trial was designed to assess the impact of AGS-004 in chronically HIV-1 infected patients. In the trial, in 29 chronically infected patients treated with AGS-004, we observed lower-than-expected levels of viral rebound at the three months ART treatment interruption and some patients experienced longer-than-expected time to detectable viral load.

In May, stage one of the phase 2 trial of AGS-004 aimed at virus eradication in adults was initiated. We believe that by combining AGS-004 with the therapy that can expose the virus to lately infected cells to the immune system, we can potentially eradicate the virus. This trial was planned to enroll six acutely infected and six chronically infected HIV patients. So far, five patients have been enrolled in the trial, and there are another five undergoing screening for eligibility to participate in the trial.

Upon completion of stage one of the trial, the patients will enter stage two of the trial when they will initiate combination therapy with AGS-004 plus a latency reversing drug.

Also, we continue to make progress with our planned phase 2 clinical trial of AGS-004 monotherapy in pediatric patients infected with HIV, that have been on ART since birth or shortly after, that have no natural immunity to the virus, because it has been suppressed their entire life.

If AGS-004 administration can generate anti-viral memory T cell responses then these adolescence would clinically resemble natural elite controllers in terms of immunologic health anti-viral immunity and exceeding low viral burden, possibly allowing long-term ART independence, which would be very exciting.

Since our last earnings call, we have had additional discussions with the NIH division of AIDS, the leadership of the International Maternal Pediatric Adolescence AIDS Clinical Trials or IMPAACT network and the pediatricians who will serve as co-PI in our protocols. We expect to finalize the protocol design and sample size for this trial by the end of September, and begin moving forward with the initiation of the trial by the end of this year.

On a separate note, I wanted to mention that we’ve recently made significant progress with our pre-clinical program involving the recombinant human protein, CD83. As a reminder, the soluble form of the CD83 protein has widespread applications in autoimmune and inflammatory diseases, as well as transplantation rejection.

We have discovered significant T cells of the mechanism of action by which, soluble CD83 can permanently turn-off undesired immune responses, without the need for continuous administration and without inducing global immunosuppression. Our most recent research study in structured function relationships has led to new pack filings, just two weeks ago.

We plan to submit a series of manuscripts detailing these discoveries to peer review journals beginning with the first submission within the next month. Going forward, we plan to exploit this new information to further refine the scope of therapeutics options to clinical development of this first-in-class recombinant protein.

I will now turn the call over to Lori, who will review our financial results for the first quarter.

Lori Harrelson

Thanks Charles. Revenue for the first three months ended June 30, 2014 was $0.5 million, compared to $1.3 million for the same period in 2013. The decrease for the period is due to decreased reimbursements under our NIH contract, associated with decreased activity within our phase 2b clinical trial of AGS-004, as this trial was winding down.

Research and development expenses for the three months ended June 30, 2014 were $10.6 million, compared to $6.1 million for the same period in 2013, an increase of 73.2%. The increase primarily reflects a $3.2 million increase in direct research and development expenses, resulting from an increase of $0.6 million in AGS-003 clinical trial expense and patient enrollment increased significantly over the same period in 2013, and $2.9 million in commercial manufacturing development efforts.

Indirect research and development expense for the three months ended June 30, 2014 increased by $1.3 million, compared to the same period in 2013. The increase is due to a higher number of employees engaged in research and development activities as of June 30, 2014.

General and administrative expenses for the three months ended June 30, 2014 were $1.9 million, compared to $0.9 million for the same period in 2013, an increase of 98.5%. This reflects an increase of $0.4 million in personnel costs, $0.2 million in outside services, and $0.3 million relating to our renewed status as a public company.

Net loss attributable to common stockholders for the three months ended June 30, 2014 was $12 million or $0.61 per common share, compared to a net loss of $5.8 million or $25.53 per common share for the same period in 2013.

Cash, cash equivalents and short-term investments totaled $71.8 million at June 30, 2014, compared to $47 million at the end of 2013. The increase results primarily from $43.4 million in net proceeds from the sale of 6.2 million shares of common stock in our initial public offering in February.

We expect that our existing cash, cash equivalents and short-term investments, including anticipated funding under our NIH contracts, will enable us to fund our operating expenses into the second half of 2016. We estimate our 2014 cash utilization will be in the $45 million to $50 million. Our expenses will be focused on the phase 3 clinical trial of AGS-003, our planned phase 2 clinical trials of AGS-003, the funding of certain costs of the planned phase 2 clinical trials of AGS-004 and the initiation of our commercial development efforts.

We expect to file our 10-Q with the U.S. Securities and Exchange Commission on August 14.

Now, I will turn the call back over to Jeff.

Jeff Abbey

Thanks, Lori. As I stated at the outset, we’re continued to be pleased with the enrollment of patients in our AGS-003 phase 3 ADAPT trial. Looking ahead, we expect to complete tumor collection by the end of the year and enrollment in first quarter of 2015.

To further the development of AGS-003 in oncology, by the end of this year, we expect to initiate two phase 2 clinical trials in early stage RCC, as well as phase 2 trials in non-clear cell mRCC and other solid tumors. We believe AGS-003 can be applied to a wide range of cancers, and are optimistic that we can generate supporting data.

For AGS-004, in the coming weeks, we expect to announce data from our phase 2b trial in chronically infected HIV patients, which we hope will further validate the ability of our Arcelis technology platform to induce important memory T cell responses. In addition, we look forward to the continuing progress of the phase 2 trial aimed at eradication of HIV in adult patients, and we anticipate initiating the phase 2 trial for elimination of anti-retroviral therapy in pediatric patients in the fourth quarter.

Also during the remainder of 2014, we expect to further progress our CD83 program, which Charles explained, as exciting potential. Importantly, in the coming weeks, we expect to announce the initiation of the construction of our new commercial manufacturing facility, which we will utilize our automated Arcelis manufacturing process, which of course we believe is critical to the successful commercialization of a fully personalized immunotherapy.

Finally, we will be presenting at a number of conferences during the remainder of the year, including Rodman and Renshaw in September, Stifel in November and Piper in December. I hope to meet with many of you during one of these conferences to discuss our strategy and upcoming milestones in detail. We are excited about the progress we have made and enthusiastic about what lies ahead.

With that, operator, we can open up the call for Q&A. Thank you.

Question-and-Answer Session


Certainly. (Operator Instructions) Our first question comes from the line of Chad Messer from Needham & Company. Your question please.

Chad Messer – Needham & Company

Great. Thanks for taking my question, and congratulations on the progress with the ADAPT trial, and of course we’re all anxiously awaiting the data from 004. My question is actually a financial one. You have guidance for cash to mid ‘16. And I was hoping you could help me with a couple of things, so I could kind of understand how that would all play out. One is the $2.9 million in manufacturing expense in the second quarter. Any insight on how much of that would be recurring over time? And then also I know ADAPT, when you done enrollment in 1Q, obviously cost for that trial was dropped. I was wondering if you could give us a sense of, how much costs for ADAPT are, sort of rolled up in the tumor collection and the processing of drug for patients? Thanks.

Jeff Abbey

Thanks Chad. I’m going to let Lori answer those questions. Thanks.

Lori Harrelson

Okay. First, I’m going to answer your question about the phase 3 ADAPT trial. So the expenses related to the trial will continue to increase over 3Q and then level up in 4Q and 1Q 2015, and then start to decrease, and will continue to decrease beyond that.

As far as the commercial manufacturing activities that is related to our manufacturing process. So to-date, we still have – do have enough funds to get us into the second half of 2016, but we are actively seeking non-dilutive funding sources to help fund additional costs related to the commercial manufacturing activities, as well as the commercial facilities.

Chad Messer – Needham & Company

Great, thanks.


Thank you. Our next question comes from the line of Charles Duncan from Piper Jaffray. Your question please.

Roy Buchanan – Piper Jaffray

Hi. It’s Roy in for Charles. Thanks for taking my question. I’ve got a question on the new phase 2 studies that you’re planning. Do you guys have any interim planned in the timing of those? Is the solid tumor study all-comers, and what do you think is the size of those studies?

Jeff Abbey

Sure. Thanks Roy. I’d let Doug answer that question.

Doug Plessinger

Yes, great questions, Roy. I can definitely indicate that the size of these trials can be relatively limited, typical phase 2 size populations within the cancer realm. So most likely between 25 to 30 patients. The advanced solid tumor trials will most likely include a hand full of tumor types, but not the classic or traditional all-comers phase 1 any advanced solid tumor type of trial. We will definitely identify tumor types where we think AGS-003 has ability to be readily comply with standard therapies and integrated to hopefully provide some clinical benefit.

As far as interims, the great news is these aren’t randomized pivotal phase 3 trials like ADAPT. So we’ll have data read-outs along the path, and you could imagine that these trials, again phase 2 in nature, will have multiple endpoints. So we’ll have response endpoints, we’ll have immunologic response endpoints, safety, and then some longer term follow-up for survival and we’ll be able to report those results as patients are enrolled and as we meet those milestones, where data is available and we can share that.

Charles Duncan – Piper Jaffray

Okay, great. Thanks. And the HIV phase 2b data. Is that going to have viral load?

Jeff Abbey

I’ll let Charles answer that one, Roy. Thanks.

Charles Nicolette

Yes, so the phase 2b data is going to have quite a large number of analysis performed beyond the impact on viral loads, the immune response analysis that’s being done is extreme depth with many tens of thousands of data points per patient collected over the course of the protocol. So it’s an enormous amount of information, also looking at blood cell dynamics CD4 T cell counts, CD8 T cells counts and a whole slew of various markers of inflammation and control of inflammation. So the sheer amount of data is what we’re shifting through now and we’re doing our best to be as thorough and accurate as we can.

Charles Duncan – Piper Jaffray

Okay. So, are you guys just going to PR that? Is there going to be a presentation, do you have a forum?

Jeff Abbey

Yes, this is Jeff. So I think the plan is that, if it is available as we expect sometime in the coming week we – since there is no upcoming conference in that timeframe, we would have a separate call to discuss that data in detail, and then it would be presented at a conference subsequently.

Charles Duncan – Piper Jaffray

Okay. That makes sense. And then more question on HIV. I guess there has been some debate about the latency reversing drugs, how well they work in humans. Does that impacting you guys decision, do you have a drug in mind right now, or what are you thinking on that?

Jeff Abbey

Charles will take that one as well.

Charles Nicolette

Yes. Sure. That’s a good question and there has been a lot of material that primarily has shed some doubt on histone deacetylase based latency reversing drugs. And large amount of that information was derived from Bob Siliciano’s laboratory using what we consider to be some artificial methods that may not fully apply in vivo, and the data that our PI on this study Dr. David Margolis has collected using that histone deacetylase inhibitor known as vorinostat stands in contradistinction to what some of the more recent data are.

So we’re going with the actual outcomes with vorinostat in HIV patients, in the same patient population that we’re working in now, and we feel that, that data is sufficient to support the study going forward under the rational that we had originally put forward.

Charles Duncan – Piper Jaffray

Okay. Very helpful. Thank you.


Thank you. (Operator Instructions) Our next question comes from the line of Tom Schrader from Stifel. Your question please.

Tom Schrader – Stifel Nicolaus

Thanks for taking the question. I am mostly interested in enrollment of the big trial. So you have 130 sites, that’s a lot. That’s I think more than Nexavar had. Is it easy to recruit sites if there is no special requirement for a specialty approach?

Jeff Abbey

Hi Tom, thanks for the question. I’ll obviously ask Doug to answer that one.

Doug Plessinger

Yes. Thanks Tom. So we’re really pleased with the 130 global sites we currently have participating in the trial. And I think one of the clear needs that we had when identifying and selecting and qualifying these sites is we needed to ensure there was a mechanism for a strong multidisciplinary approach to the care of patients with advanced kidney cancer, where both the surgeons as well as medical oncologists work closely together, whether that be in the same facility or within the same geographic region.

So from that perspective, we’re very fortunate because we have established, what’s now a long-standing relationship and collaboration with the Society of Urologic Oncology, which is a group of specialists on the surgical side of things for patients with advanced kidney cancer. And many of those surgeons here in North America are just fitting in trial and contribute to a great deal to the enrollment success we’ve have to-date, and particularly enrollment progress we’ve made thus far in 2014.

Tom Schrader – Stifel Nicolaus

Okay. And just looking at your screened accepted rate, 190 out of 530, do you expect that to get better? Would that be the final rate? Why are you turning people away, and is it mostly the rate now a function of inexperienced people, or how do you expect that to play out over time?

Doug Plessinger

Yes, excellent question. So it provides the opportunity for me to clarify and define the differences. So first and foremost, collecting tumor and consenting 530 patients will not just yield 190 enrolled randomized patients. Throughout the life of this trial and certainly consistent with our phase 2 experience, we tend to see about 50% attrition rate or screen failure rate in the advanced kidney cancer population. And thus far, there haven’t really been many surprises for us on the phase 3 trial.

The primary reasons why patients are screen failing are not eligible for participate in the treatment phase of the trial after surgery and successful tumor collection, roll down to three primary reasons. One, because a large percent of these patients that have screen failed have what’s known as non-clear cell metastatic RCC or non-clear cell histology. This trial is designed to enroll only patients with predominantly clear cell, and the reason being is that sunitinib and the other targeted therapies have been developed and approved for the treatment of predominantly clear cell mRCC. So that’s critical for the trial design, and certainly for a single pivotal study like ADAPT.

The second reason why patients are not eligible is, because of their prognosis and/or their diminished performance status and multiple risk factors following surgery that would indicate that you don’t have an opportunity to or don’t have an expected survival longer than six months. And so it’s really critical for us in this type of study with an immunotherapy like AGS-003 to ensure that we’re selecting good quality patients who could potentially be stabilized by initiation of targeted therapy, and ultimately have the opportunity to benefit from five or more doses of AGS-003.

And lastly, the third core reason why about 50% of patients aren’t eligible is because of the comorbidities. And those comorbidities could be cardiac, it can be gastrointestinal, it could be renal, reasons why they aren’t appropriate to move onto targeted therapies like sunitinib, which is unfortunate, because if we had other trials and opportunities, they might be good patients for AGS-003 alone or what other therapies, but in this particular case, they are not good candidates, not appropriate candidates for treatment with sunitinib initially, and that’s why they are not eligible for the treatment phase of the trial.

Tom Schrader – Stifel Nicolaus

I suppose I could look this up, but once sunitinib knew that they were betting all the marvels on clear cell. Do you know what their screening rates were?

Doug Plessinger

Their screening rates would have been very different, because they were selecting a population, in many cases, that had a distant nephrectomy and didn’t present with this poor prognosis disease known as synchronous metastatic RCC. So their screen failure rates may have been less. I don’t know that they’ve ever published that to be honest with you.

Tom Schrader – Stifel Nicolaus


Doug Plessinger

Certainly it isn’t in the primary publications going back to the pivotal phase 3 trial.

Tom Schrader – Stifel Nicolaus


Jeff Abbey

And just, Tom, to further clarify what Doug has said about the screen failure rate and the number of tumors collected and the number enrolled and randomized, there is about an 8 to 12 week lag on average from tumor collection to randomization and enrollment. So that’s why with the 530, we’re expecting 265-ish to be ultimately randomized out of those 530.

So the 190 at that point in time just indicates that lag in the process from the time of screening to the time of actual enrollment.

Tom Schrader – Stifel Nicolaus

Okay, thank you.


Thank you. This does conclude the question-and-answer session of today’s program. I would now like to turn the call back to Jeff Abbey, President and Chief Executive Officer for closing remarks.

Jeff Abbey

Okay, thank you. I just want to thank everybody for participating in the call today. And first and foremost and most importantly, thanking the patients, their families and the doctors participating in all of our clinical trials, and also hope to have many of you on our next call, which we expect will be discussion of the phase 2b AGS-004 HIV trial, as I previously mentioned. So that concludes the call from our end. Thank you.


Thank you, ladies and gentlemen, for your participation in today’s conference. This does conclude the program. You may now disconnect. Good day.

Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to All other use is prohibited.


If you have any additional questions about our online transcripts, please contact us at: Thank you!